A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study is testing a new drug called BL-M11D1 — an antibody-drug conjugate that targets a protein called CD33 found on leukemia cells — in patients with acute myeloid leukemia (AML, a blood cancer) that has come back or stopped responding to prior treatment. The drug attaches to CD33-positive cancer cells and delivers a toxic payload directly to them. **You may be eligible if:** - You are 18–75 years old - You have been diagnosed with acute myeloid leukemia (AML) that is CD33-positive on lab testing - Your leukemia has relapsed or is no longer responding to previous treatments (relapsed/refractory AML) - Your bone marrow has at least 5% blast cells (immature cancer cells) - You are in reasonably good health (ECOG 0–2) with a life expectancy of at least 3 months - Your white blood cell count is below 25×10⁹/L before the first dose - Your organ function meets the study requirements **You may NOT be eligible if:** - You have acute promyelocytic leukemia (a specific AML subtype) or AML transformed from chronic myeloid leukemia - You have received another anti-cancer treatment within 4 weeks (or within 5 half-lives) before starting the study drug - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.